Home Casteddu.com FAQ My Amedeo About Flying Publisher   

The Medical Article of the Year 2008:
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78.
Free full-text


  Malignant Melanoma

  Free Subscription


Articles published in J Immunother

Retrieve available abstracts of 36 articles:
HTML format

Single Articles


    July 2008
  1. CARLSSON B , Sadeghi A, Bengtsson M, Wagenius G, et al
    Effector T Cell Analysis of Melanoma Tumor-infiltrating Lymphocyte Cultures Using HLA-ABC Semimatched Melanoma Cell Lines.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


  2. RIDOLFI L , Cangini D, Galassi R, Passardi A, et al
    Reversible, PET-positive, Generalized Lymphadenopathy and Splenomegaly During High-dose Interferon-alpha-2b Adjuvant Therapy for Melanoma.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


    June 2008
  3. ROSSI GR , Mautino MR, Awwad DZ, Husske K, et al
    Allogeneic Melanoma Vaccine Expressing alphaGal Epitopes Induces Antitumor Immunity to Autologous Antigens in Mice Without Signs of Toxicity.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


  4. JIANG Q , Wei H, Tian Z
    IFN-producing Killer Dendritic Cells Contribute to the Inhibitory Effect of Poly I:C on the Progression of Murine Melanoma.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


  5. ACQUAVELLA N , Kluger H, Rhee J, Farber L, et al
    Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


  6. BREUNIS WB , Tarazona-Santos E, Chen R, Kiley M, et al
    Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


  7. REDMAN BG , Chang AE, Whitfield J, Esper P, et al
    Phase Ib Trial Assessing Autologous, Tumor-pulsed Dendritic Cells as a Vaccine Administered With or Without IL-2 in Patients With Metastatic Melanoma.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


    May 2008
  8. CAPOBIANCO A , Manfredi AA, Monno A, Rovere-Querini P, et al
    Melanoma and Lymphoma Rejection Associated With Eosinophil Infiltration Upon Intratumoral Injection of Dendritic and NK/LAK Cells.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


  9. HOFMANN MA , Kors C, Audring H, Walden P, et al
    Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


    April 2008
  10. VON EULER H , Sadeghi A, Carlsson B, Rivera P, et al
    Efficient Adenovector CD40 Ligand Immunotherapy of Canine Malignant Melanoma.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


  11. KOIKE N , Pilon-Thomas S, Mule JJ
    Nonmyeloablative Chemotherapy Followed by T-cell Adoptive Transfer and Dendritic Cell-based Vaccination Results in Rejection of Established Melanoma.
    J Immunother. 2008;.
    PubMed     Related articles    Abstract available


    February 2008
  12. WEBER J , Boswell W, Smith J, Hersh E, et al
    Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    J Immunother. 2008;31:215-23.
    PubMed     Related articles    Abstract available


  13. POWELL DJ JR , Attia P, Ghetie V, Schindler J, et al
    Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.
    J Immunother. 2008;31:189-98.
    PubMed     Related articles    Abstract available


  14. WEIDE B , Carralot JP, Reese A, Scheel B, et al
    Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.
    J Immunother. 2008;31:180-8.
    PubMed     Related articles    Abstract available


    January 2008
  15. RUTTINGER D , Li R, Poehlein CH, Haley D, et al
    Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.
    J Immunother. 2008;31:43-51.
    PubMed     Related articles    Abstract available


    April 2007
  16. FRIEBE A , Schwarz MJ, Schmid-Wendtner M, Volkenandt M, et al
    Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
    J Immunother. 2007;30:333-7.
    PubMed     Related articles    Abstract available


    February 2007
  17. APPAY V , Voelter V, Rufer N, Reynard S, et al
    Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
    J Immunother. 2007;30:240-50.
    PubMed     Related articles    Abstract available


  18. BINS A , Mallo H, Sein J, van den Bogaard C, et al
    Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
    J Immunother. 2007;30:234-9.
    PubMed     Related articles    Abstract available


    January 2007
  19. SMITH FO , Goff SL, Klapper JA, Levy C, et al
    Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.
    J Immunother. 2007;30:130.
    PubMed     Related articles   


  20. ZHAO Y , Sun Y, Niu Z, Li Q, et al
    A novel approach to generate host antitumor T cells: adoptive immunotherapy by T cells maturing in xenogeneic thymus.
    J Immunother. 2007;30:83-8.
    PubMed     Related articles    Abstract available


  21. WESA A , Kalinski P, Kirkwood JM, Tatsumi T, et al
    Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro.
    J Immunother. 2007;30:75-82.
    PubMed     Related articles    Abstract available


  22. AGGER R , Petersen MS, Petersen CC, Hansen SB, et al
    T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging.
    J Immunother. 2007;30:29-39.
    PubMed     Related articles    Abstract available


    September 2006
  23. PALUCKA AK , Ueno H, Connolly J, Kerneis-Norvell F, et al
    Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity.
    J Immunother. 2006;29:545-557.
    PubMed     Related articles    Abstract available


  24. DAVIS ID , Chen Q, Morris L, Quirk J, et al
    Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    J Immunother. 2006;29:499-511.
    PubMed     Related articles    Abstract available


    July 2006
  25. MAKER AV , Yang JC, Sherry RM, Topalian SL, et al
    Intrapatient Dose Escalation of Anti-CTLA-4 Antibody in Patients With Metastatic Melanoma.
    J Immunother. 2006;29:455-463.
    PubMed     Related articles    Abstract available


  26. BARRIO MM , de Motta PT, Kaplan J, von Euw EM, et al
    A Phase I Study of an Allogeneic Cell Vaccine (VACCIMEL) With GM-CSF in Melanoma Patients.
    J Immunother. 2006;29:444-454.
    PubMed     Related articles    Abstract available


  27. PILON-THOMAS S , Li W, Briggs JJ, Djeu J, et al
    Immunostimulatory Effects of CpG-ODN Upon Dendritic Cell-Based Immunotherapy in a Murine Melanoma Model.
    J Immunother. 2006;29:381-7.
    PubMed     Related articles    Abstract available


  28. ZHAO Y , Zheng Z, Khong HT, Rosenberg SA, et al
    Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.
    J Immunother. 2006;29:398-406.
    PubMed     Related articles    Abstract available   Free Full Text


    May 2006
  29. JEROME V , Graser A, Muller R, Kontermann RE, et al
    Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    J Immunother. 2006;29:294-305.
    PubMed     Related articles    Abstract available


  30. SHAFER-WEAVER K , Rosenberg S, Strobl S, Gregory Alvord W, et al
    Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.
    J Immunother. 2006;29:328-35.
    PubMed     Related articles    Abstract available


  31. KIM TS , Chopra A, O-Sullivan IS, Cohen EP, et al
    Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells: Enrichment of the vaccine for immunotherapeutic cells.
    J Immunother. 2006;29:261-73.
    PubMed     Related articles    Abstract available


  32. PETERSEN CC , Petersen MS, Agger R, Hokland ME, et al
    Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection.
    J Immunother. 2006;29:241-9.
    PubMed     Related articles    Abstract available


    March 2006
  33. ROSENBERG SA , Sherry RM, Morton KE, Yang JC, et al
    Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
    J Immunother. 2006;29:224-31.
    PubMed     Related articles    Abstract available   Free Full Text


  34. LETSCH A , Keilholz U, Kern F, Asemissen AM, et al
    Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptides.
    J Immunother. 2006;29:201-7.
    PubMed     Related articles    Abstract available


    November 2005
  35. WEISS JM , Allen C, Shivakumar R, Feller S, et al
    Efficient responses in a murine renal tumor model by electroloading dendritic cells with whole-tumor lysate.
    J Immunother. 2005;28:542-50.
    PubMed     Related articles    Abstract available


  36. HINRICHS CS , Palmer DC, Rosenberg SA, Restifo NP, et al
    Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
    J Immunother. 2005;28:517-24.
    PubMed     Related articles    Abstract available


Thank you for your interest in scientific medicine.


Amedeo is a Bernd Sebastian Kamps website.

   Design: